Bayesian Capital Management, LP Viking Therapeutics, Inc. Transaction History

Bayesian Capital Management, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$14.84 - $24.79 $247,293 - $413,100	16,664 New	16,664 $270,000
Q2 2021 Aug 13, 2021	SELL	$5.19 - $6.73 $66,432 - $86,144	-12,800 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$5.74 - $9.67 $73,472 - $123,776	12,800 New	12,800 $81,000
Q4 2018 Feb 13, 2019	SELL	$7.16 - $16.21 $83,056 - $188,036	-11,600 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$9.7 - $19.65 $112,519 - $227,939	11,600 New	11,600 $202,000

442

63.3M

6.23M

2.97M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $4.83B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Bayesian Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Bayesian Capital Management, LP with notifications on news.